ASP Isotopes (NASDAQ:ASPI) Trading 10.1% Higher – What’s Next?

ASP Isotopes Inc. (NASDAQ:ASPI)’s share price rose 10.1% on Thursday . The stock traded as high as $7.32 and last traded at $7.3420. Approximately 1,633,294 shares were traded during trading, a decline of 68% from the average daily volume of 5,049,644 shares. The stock had previously closed at $6.67.

Analyst Ratings Changes

ASPI has been the topic of several research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research report on Tuesday, April 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a research report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, ASP Isotopes presently has a consensus rating of “Hold” and a consensus target price of $13.00.

ASP Isotopes Stock Performance

The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.37 and a current ratio of 4.39. The business has a 50-day moving average price of $5.12 and a 200 day moving average price of $5.90. The stock has a market capitalization of $969.96 million, a P/E ratio of -3.70 and a beta of 3.26.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.The firm had revenue of $8.36 million for the quarter, compared to analysts’ expectations of $3.68 million.

Insider Transactions at ASP Isotopes

In other news, CFO Heather Kiessling sold 23,124 shares of ASP Isotopes stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $5.48, for a total value of $126,719.52. Following the completion of the transaction, the chief financial officer owned 709,376 shares of the company’s stock, valued at $3,887,380.48. The trade was a 3.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Duncan Moore sold 11,642 shares of ASP Isotopes stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $5.21, for a total value of $60,654.82. Following the completion of the transaction, the director directly owned 1,044,928 shares of the company’s stock, valued at approximately $5,444,074.88. This represents a 1.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 90,704 shares of company stock valued at $463,252 in the last quarter. 14.40% of the stock is owned by insiders.

Hedge Funds Weigh In On ASP Isotopes

Several large investors have recently modified their holdings of ASPI. Quantbot Technologies LP bought a new position in ASP Isotopes in the 3rd quarter valued at approximately $34,000. BNP Paribas Financial Markets lifted its position in ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after acquiring an additional 2,548 shares in the last quarter. State of Wyoming bought a new position in ASP Isotopes in the 1st quarter valued at approximately $29,000. Close Asset Management Ltd bought a new position in ASP Isotopes in the 3rd quarter valued at approximately $72,000. Finally, Legal & General Group Plc lifted its position in ASP Isotopes by 30.4% in the 3rd quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after acquiring an additional 1,953 shares in the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.